---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Effect on quality measures"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Effect on quality measures. Topics: MIPS Quality ID 14: AMD dilated macular examination, 2023 specification; Removal of MIPS Quality ID 14 for the 2024 performance year; IRIS Registry QCDR measure IRIS63: limited to exudative AMD. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Vonaprument on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### MIPS Quality ID 14: AMD dilated macular examination, 2023 specification

> “Percentage of patients aged 50 years and older with a diagnosis of age-related macular degeneration (AMD) who had a dilated macular examination performed which included documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage AND the level of macular degeneration severity during one or more office visits within the 12 month performance period.”
> “Process”
> “Geographic Atrophy – The advanced form of non-neovascular AMD, will have one or more zones of well- demarcated retinal pigment epithelial and/or choriocapillaris atrophy.”

Source: [Centers for Medicare & Medicaid Services Quality ID 14 (2023)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2023_Measure_014_MIPSCQM.pdf)

<a id="topic-2.1.2.13-2"></a>

### Removal of MIPS Quality ID 14 for the 2024 performance year

> “CMS removed measure 14 because it had been topped out for several years. CMS considers process-based measures to be topped out when they have a median performance rate of at least 95%. The agency is concerned that such measures offer little opportunity for performance improvement.”

Source: [American Academy of Ophthalmology MIPS 2024 quality changes (2023)](https://www.aao.org/eyenet/article/mips-2024-what-s-new-with-quality)

<a id="topic-2.1.2.13-3"></a>

### IRIS Registry QCDR measure IRIS63: limited to exudative AMD

> “Percentage of patients with a diagnosis of exudative age-related macular degeneration, being treated with anti-VEGF agents, with a gain of 1 Snellen line or more”

Source: [American Academy of Ophthalmology IRIS63 measure specification](https://www.aao.org/medicare/quality-reporting-measure/iris63-exudative-age-related-macular-degeneration)

<a id="topic-2.1.2.13-4"></a>

### Product-specific effect on quality measures

No evidence found.

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
